This is Willow.
Pure. Precise. Proven.
This is Willow.
Pure. Precise. Proven.
Our Mission
Our goal at Willow is to commercialize high-value bio-products derived from plants. We do this by making key discoveries in plant genomics, and then translating these newly discovered genetic elements and biochemical strategies into the appropriate commercial host organism. We invite you to partner with us to enhance the success of your manufacturing program.
About Us
At Willow, our business is the discovery and commercialization of high-value bioproducts through biosynthesis.
What We Do
Commercial biosynthesis starts with understanding the plant’s genomics and pathway biochemistry, but yields a higher grade product for industrial and pharmaceutical needs.
Investors
Get more details about Willow.
Contact Us
Reach out and connect with us. Sign up for our newsletter.
Work at Willow
At Willow our business is to enable the commercialization of high-value bioproducts. We achieve this by making and deploying key discoveries in plant genomics and pathway biochemistry. Newly discovered genetic elements and biochemical mechanisms are transferred or translated into an appropriate industrial host organism, and optimized for maximum yield.
News and Press Releases
Willow Biosciences and Noramco Announce Joint Development of Biosynthesis Platform for Cannabidiol
CALGARY, June 4, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW), a leading developer of biosynthetic production systems [...]
Willow Biosciences and Tuatara Capital Announce Exercise of Warrants
CALGARY, May 27, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) and Tuatara Capital Fund II, L.P. ("Tuatara") are pleased [...]
Willow Biosciences Inc. Announces Appointment of Vice President, Corporate Development, Stock Option Grant and Investor Presentation
CALGARY, May 2, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW) is pleased to announce that Troy Talkkari has joined the [...]
Willow Biosciences
Be the first to know. Sign up to receive news,
updates, investor information and more.